Roux-en-Y gastric bypass versus sleeve gastrectomy: a meta-analysis
Date
2014-03-31
Authors
Nietz, Sarah Lena
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Morbid obesity is a growing pandemic and is a direct cause of diseases such as type 2
diabetes. Bariatric surgery is an effective long-term treatment modality. There are several
procedures that have been described, however, sleeve gastrectomy (SG) has gained
popularity despite a paucity of evidence for its use. In contrast, the Roux-en-Y gastric
bypass (RYGB) has been validated and is considered the gold standard in bariatric
surgery. Currently there is no evidence proving superiority of RYGB over SG.
Objectives
To determine whether SG is as effective as RYGB.
Methods
Randomized controlled trials (RCTs) comparing adults undergoing laparoscopic RYGB or
SG for treatment of morbid obesity were compared in a fixed-effect model meta-analysis.
Outcomes included measures of weight loss, improvement of comorbidities, procedurerelated
morbidity and mortality, and changes in gut hormone levels. Heterogeneity was
assessed using the I2 test, and all studies were assessed for bias.
Results
Eight RCTs were included in this review. No mortalities were reported. SG had lower rates
of morbidity, re-operation and re-hospitalization, but this was not statistically significant.
There was no significant difference between SG and RYGB for parameters of weight loss
and diabetes resolution after 12 months follow-up. RYGB significantly improved
dyslipidaemia with statistical differences in triglyceride and LDL reduction (MD=-0.17,
14
p=0.05 and MD=-0.43, p=0.002 respectively). SG lowered fasting ghrelin levels
(MD=342.96, p=<0.00001), RYGB lowered leptin levels (MD= -6.96, p=0.02), and there
was no difference in PYY levels.
Conclusions
SG and RYGB were equivalent in procedural morbidity and mortality, weight loss and
parameters of diabetes resolution at 12 month follow-up. RYGB had a superior resolution
of dyslipidaemia.